Skip to main content

Pfizer Inc. (PFE) Stock Price & Market Analysis

PFE · NYSE · Pharmaceuticals

Last confirmed priceEarlier session print

$27.80

▼ -$0.3200(-1.14%)4:01 PM ET - vs previous close

Quote as of Oct 2, 2026, 4:01 PM EDT

Regular-session close · Oct 2, 2026, 4:01 PM EDT.

Yahoo Finance · delayed, minutes not stated · as of Oct 2, 2026, 4:01 PM EDT · current source

Last session51%
$27.44L Oct 2 '26$28.15H Oct 2 '26
52-week range75%
$23.62$29.21H Sep 3 '26
Long-term rangesAvailable history
Available history(2000-10-04)53%
$5.30L Mar 2 '09$47.78H Dec 20 '21

Price history: 2000-10-04–2026-10-02. Earlier trading may not be included. Highs and lows use intraday prices when available, otherwise closing prices. The 52-week range is reported separately by Yahoo Finance.

Loading price chart…

Data dates

PriceAt closeLast traded

FundamentalsLast checked

AnalystLast checked

Loading upcoming events…

Reported fundamentals

PFE financial overview

Annual revenue

USD 62.58B

Sales for the fiscal year ended Dec 31, 2025. This is not trailing twelve-month revenue.

Revenue change

-1.6%

Change versus the fiscal year ended Dec 31, 2024.

Net profit margin

12.4%

Net income divided by revenue for the fiscal year ended Dec 31, 2025. This is not the trailing margin.

These reported results describe the business’s recent scale and profitability. Compare cash generation and valuation before forming an investment view; historical growth is not a forecast.

Company · Profile

About Pfizer Inc. (PFE)

Sector, leadership, and how Pfizer Inc. earns its revenue.

Pfizer Inc.

NYSE · PFE · US

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Company overview as of Oct 5, 2026.

Sector
Healthcare
Industry
Pharmaceuticals
Headquarters
New York, NY, United States
Country
US
Founded
1849
Employees
75,000
CEO
Dr. Albert Bourla D.V.M., Ph.D.
Exchange
NYSE
Business model & operating evidence

Company website ↗

AI business exposure

Revenue exposure
AI-specific revenue is not separated in the available company statements.
Capital-spending dependency
No reviewed quantitative dependency model is available.
Compute role
See the sourced business description; AI labels do not establish compute revenue.
Platform examples
An exhaustive, consistently defined product inventory is unavailable.
Ecosystem links
Supplier and customer links require reviewed disclosures.

Narrative versus numbers

Demand is expanding

Supporting observation: 2.6%

Year-over-year growth in the latest quarter. This differs from the fiscal-year revenue change shown above. · SEC Companyfacts · 2026-06-28

Growth produces accounting profit

Supporting observation: 6.8%

Reported-period net margin. A positive figure supports accounting profitability, not cash generation. · SEC Companyfacts · 2026-10-05T08:53:31.834Z

The business generates cash after investment

Supporting observation: USD 302M

Latest reported free cash flow. It is not a forecast and may cover a different period from the fiscal-year figures above. · SEC Companyfacts · 2026-06-28

These are explicit tests of individual claims, not an overall bull/bear rating. Demand growth can coexist with valuation, concentration and financing risk.

Operating measures

Revenue
$15.03Bquarter ended Jun 28, 2026
EPS
-$0.04quarter ended Jun 28, 2026
Capital expenditure
$533.00Mquarter ended Jun 28, 2026
Free cash flow
$302.00Mquarter ended Jun 28, 2026
Free cash flow margin
2.0%quarter ended Jun 28, 2026
Revenue growth year over year
2.6%quarter ended Jun 28, 2026

Leadership

Chief executive officerDr. Albert Bourla D.V.M., Ph.D.

Source: Yahoo Finance · Oct 5, 2026

Ownership filings and insider activity
Competitors & comparisons

Loading competitor research…

Loading fund exposure…

Governance & sustainability

Find proxy statements and annual reports

Read PFE news & coverage
All data sources

Search the dated figures used for this view. Each entry identifies its units, reporting period and calculation status.

Browse all companies and funds
Research tools
Premarket

Regular hours: 9:30 AM–4:00 PM America/New_York

Next open: 2026-10-05 · 9:30 AM America/New_York

Exchange calendar includes scheduled holidays and early closes. Extended-session prices appear separately only when supplied by the quote source.